In 2022, De Nunzio et al. reported on the combination therapy of alpha-1 blockers with HSE versus monotherapy in the treatment of LUTS/BPH from five different clinical studies (mean age ranged from 55.3 to 68.3, representing 1292 subjects with HSE dosing at 320 mg/day and alpha-1 blocker(s) dosing 0.2 to 0.4 mg/day from 6 to 13.5 months) [157]. Here, PSMA6 is linked to benign prostatic hyperplasia.